Finance

Lists
Why is ZTS up २.३७%?
Dive Deeper
ZTS:NYSE
Zoetis Inc
US$ ७४.८१
+२.३७%
(+१.७३) 1D
US$ ७३.९०
-१.२१% (-०.९१)
After hours
Closed: अक्टोबर ९, १६:०३:१६ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
US$ ७३.०४
High
US$ ७४.८५
Low
US$ ७३.००
Mkt. cap
३०.९१ अरब
Avg. vol.
४५.८५ लाख
Volume
२९.१२ लाख
Dividend
२.८३%
Quarterly dividend
US$ ०.५३
Ex-dividend date
२०२६ जुलाई २०
P/E ratio
१२.३१
52-wk high
US$ १४८.३०
52-wk low
US$ ६८.७७
EPS
US$ ६.०८
Beta
०.७४
Shares outstanding
४१.३२ करोड
No. of employees
१४ हजार
Open
US$ ७३.०४
High
US$ ७४.८५
Low
US$ ७३.००
Mkt. cap
३०.९१ अरब
Avg. vol.
४५.८५ लाख
Volume
२९.१२ लाख
Dividend
२.८३%
Quarterly dividend
US$ ०.५३
Ex-dividend date
२०२६ जुलाई २०
P/E ratio
१२.३१
52-wk high
US$ १४८.३०
52-wk low
US$ ६८.७७
EPS
US$ ६.०८
Beta
०.७४
Shares outstanding
४१.३२ करोड
No. of employees
१४ हजार
News stories
From web sources and news partners
Zacks
Zacks
·
१ घण्टा पहिले
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
Yahoo Finance
Yahoo Finance
·
२ घण्टा पहिले
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
Benzinga
Benzinga
·
६ घण्टा पहिले
10 Health Care Stocks Whale Activity In Today’s Session
Simply Wall Street
Simply Wall Street
·
२० घण्टा पहिले
Zoetis (ZTS) Gets A Fresh Heartworm Boost While Fair Value Stays In Focus
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees१४.५ हजार
Founded१९५२
HeadquartersParsippany-Troy Hills, न्यु जर्सी, संयुक्त राज्य अमेरिका
Sector-
Websitezoetis.com
Analyst ratings
Based on 11 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
4
Hold
7
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current US$ ७४.८१
US$ ११५.०० (+५३.७२%)
Average
US$ ९०.७१ (+२१.२५%)
Lowest
US$ ८०.०० (+६.९४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Jonathan Block
Stifel Nicolaus
Hold
Reiterated
-
-
09/18/2026
Steve Scala
TD Cowen
Buy
Reiterated
US$ ९४.००
+२५.७%
08/25/2026
Glen Santangelo
Barclays
Hold
Reiterated
US$ ८५.००
+१३.६%
08/17/2026
Chris Schott
J.P. Morgan
Buy
Maintained
US$ ११५.००
+५३.७%
08/10/2026
Daniel Grosslight
Citi
Buy
Maintained
US$ ९६.००
+२८.३%
08/11/2026
David Westenberg
Piper Sandler
Hold
Maintained
US$ ८०.००
+६.९%
08/10/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
US$ ८५.००
+१३.६%
08/10/2026
Andrea Alfonso
UBS
Hold
Reiterated
US$ ८०.००
+६.९%
08/07/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
US$ ९५.००
+२७%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
05/08/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
US$ १३१.००
+७५.१%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
US$ १६०.००
+११३.९%
02/26/2026
Last report
२०२६ अगस्ट ६
Fiscal period
Q2 2026
US$ १.८७ / US$ १.८५
+०.९५%beat
Revenue / Est. (USD)
२.४७ अरब / २.५१ अरब
-१.७५%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
२.४० अरब
२.३९ अरब
२.२६ अरब
२.४७ अरब
Cost of goods sold
६८.२० करोड
७१.१० करोड
६४.०० करोड
६७.०० करोड
Cost of revenue
६८.२० करोड
७१.१० करोड
६४.०० करोड
६७.०० करोड
Research and development expenses
१७.०० करोड
१९.९० करोड
१८.०० करोड
१७.३० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५७.२० करोड
६१.८० करोड
५८.४० करोड
५८.९० करोड
Operating expense
७७.४० करोड
८४.८० करोड
७९.५० करोड
७९.३० करोड
Total operating expenses
१.४६ अरब
१.५६ अरब
१.४४ अरब
१.४६ अरब
Operating income
९४.४० करोड
८२.८० करोड
८२.७० करोड
१.०० अरब
Other non operating income
-
-६०.०० लाख
-१०.०० लाख
-२०.०० लाख
EBT including unusual items
८८.७० करोड
७६.१० करोड
७५.८० करोड
८६.६० करोड
EBT excluding unusual items
८९.९० करोड
७८.०० करोड
७७.९० करोड
९४.८० करोड
Income tax expense
१६.६० करोड
१५.८० करोड
१५.७० करोड
१७.५० करोड
Effective tax rate
१८.७१%
२०.७६%
२०.७१%
२०.२१%
Other operating expenses
-
-
-
-
Net income
७२.१० करोड
६०.३० करोड
६०.१० करोड
६९.१० करोड
Net profit margin
३०.०४%
२५.२६%
२६.५७%
२८.००%
Earnings per share
१.७०
१.४८
१.५३
१.८७
Interest and investment income
२.६० करोड
२.५० करोड
२.१० करोड
१.६० करोड
Interest expense
-५.८० करोड
-५.७० करोड
-६.२० करोड
-६.१० करोड
Net interest expenses
-३.२० करोड
-३.२० करोड
-४.१० करोड
-४.५० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
१.०७ अरब
९०.३० करोड
९४.६० करोड
१.१२ अरब
Gain or loss from assets sale
-
-
-६०.०० लाख
-१०.०० लाख
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू